Printer Friendly

Stressgen Biotechnologies Announces 2004 Financial Results; - Company Continuing its Focus on Commercializing HspE7 -.

SAN DIEGO, CA, March 14 /PRNewswire-FirstCall/ -- Stressgen Biotechnologies Corporation (TSX: SSB) announced today financial results for the year ended December 31, 2004. All amounts, unless specified otherwise, are in Canadian dollars.

For the year ended December 31, 2004, the Company reported a net loss from continuing operations of $31,845,000, or $0.44 (US$0.34) per share, compared to a net loss of $17,663,000, or $0.29 (US$0.21) per share for the year ended December 31, 2003.

For the year ended December 31, 2004, the Company reported a total net loss of $30,265,000, or $0.42 (US$0.32) per share, compared to a net loss of $16,245,000, or $0.26 (US$0.19) per share for the year ended December 31, 2003. The Company had cash and short-term investments related to continuing operations of $21,578,000 and cash and short-term investments of $1,066,000 related to discontinued operations at December 31, 2004. During the year, the Company used $28,020,000 to fund both continuing and discontinued operating activities.

Effective January 1, 2004, the Company adopted the recommendations of the Canadian Institute of Chartered Accountants (CICA) Handbook section 3870, Stock-Based Compensation and Other Stock-Based Payment. The impact on net loss of this accounting change was $1,284,000 year ended December 31, 2004.

 Progress with HspE7

 - Initiated process development and scale-up of the manufacturing
 process to support manufacturing commercial grade HspE7 in preparation
 for Phase III pivotal trial in RRP.

 - Held an End-of-Phase II meeting with the U.S. Food and Drug
 Administration (FDA). As a result of these discussions, a path forward
 for the clinical development of HspE7 for recurrent respiratory
 papillomatosis (RRP) was identified. Following FDA's recommendation,
 Stressgen will be submitting a final pivotal clinical trial protocol
 for a Special Protocol Assessment (SPA). Under a SPA, the sponsor and
 the FDA formally agree to the details of the study protocol.

 - Presented data at the 12th International Congress of Immunology
 demonstrating that HspE7 induces strong and durable cellular responses
 to the human papillomavirus (HPV) E7 protein in normal and
 immunocomprised mice.

 - Broadened the clinical program for its lead drug candidate, HspE7,
 through the enrollment of patients in a Phase II clinical trial to
 investigate HspE7 in patients with internal genital warts. All
 30 patients in this trial have been enrolled.

 - Announced a 40 percent response rate in a 21-patient trial of our lead
 drug product candidate, HspE7, in high grade cervical dysplasia.
 Patients in the study were scheduled to undergo Loop Electrocautery
 Excision Procedure (LEEP), a standard surgical procedure for patients
 with high grade dysplasia, to remove the affected area and to evaluate
 the effect of HspE7. This result is an early response rate for HspE7
 as the LEEP was performed only two months following the last dose of

 Intellectual Property

 - Broadened the Company's patent estate in the U.S. covering the use of
 HspE7 to treat patients with Recurrent Respiratory Papillomatosis
 (RRP). This new U.S. patent covers a method of treating a patient with
 RRP using a fusion protein comprised of a heat shock protein from the
 Hsp60 family, which includes Hsp65, and an HPV (type 16) E7 antigen.
 This patent provides additional patent exclusivity for HspE7 to treat
 RRP patients through June 26, 2021.

 Financial Achievements

 - In February 2004, the Company filed an amended preliminary prospectus
 in Canada for the sale of common shares. Management and the board of
 directors are reviewing alternative sources of revenue and strategic
 transactions in connection with our financial needs. The Company would
 use the proceeds of the offering to fund development and
 commercialization of HspE7, its lead product candidate.

 Assuming the Company raises approximately $15 million and sells the
 bioreagent business, the Company will have sufficient resources to
 fund operations into 2006 at current spending levels. If the Company
 does not raise at least that amount of cash, it may need to modify or
 cancel agreements with external contractors, and make changes to
 staffing level which would impact the development timelines of HspE7.
 Regardless of the funding the Company receives, it will execute the
 operational plan necessary to fund operations into 2006.

 - Grew the bioreagent business in 2004 by broadening product lines,
 improving marketing and expanding distribution channels. The Company
 has a plan to sell the bioreagent business in 2005 in order to focus
 resources on developing and commercializing HspE7. The bioreagent
 business has been accounted for as a discontinued operation in the
 December 31, 2004 financial statements.

 About Stressgen Biotechnologies Corporation:

Stressgen, a biopharmaceutical company, focuses on the discovery, development and commercialization of innovative therapeutic vaccines for the treatment of infectious diseases and cancer. The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. Stressgen uses the Canadian dollar as its functional currency. Monetary assets and liabilities that are denominated in U.S. dollars are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Revenues and expenses are translated at the average rate of exchange for the month of such transactions.
 About HspE7, Lead Product Candidate:

HspE7 is a novel CoVal(TM) fusion therapeutic vaccine for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common causes of sexually transmitted diseases in the world. An estimated 80 percent of sexually active men and women are infected by genital HPV at some point in their lives. Approximately 5.5 million new sexually transmitted HPV infections are reported in the U.S. each year. At least 20 million people in the U.S. are already infected. HPV infection can result in diseases including internal and external genital warts and precancerous conditions, such as cervical and anal dysplasia. Precancerous HPV-related conditions can progress into life-threatening diseases, including cervical, anal, and head and neck cancers.
 About CoVal(TM) Fusion Proteins:

Stressgen capitalizes upon the immunostimulatory powers of heat shock proteins utilizing recombinant technology to fuse, or covalently link, a stress protein with a protein antigen to create a single hybrid protein designed to trigger the immune system to recognize that antigen. For more information about CoVal(TM) fusion technology, or Stressgen, please visit the website located at

In addition to discussing 2004 financial results, this press release contains forward-looking statements, including references to current plans for developing HspE7, potential financing transactions, the length of time we expect current financial resources to last and the period of exclusivity intellectual property may convey. Our forward-looking statements involve risks and uncertainties. They assume that we will obtain the financial resources to continue as a going concern. Important factors that could cause our actual results to differ materially from those referred to in our forward-looking statements include: whether we will be able to secure additional sources of capital; whether we will be able to keep clinical trials of HspE7 on schedule; whether HspE7 will receive approval from regulatory agencies for one or more indications; whether we can attract and retain strategic partners; and the risks identified in our annual report filed with the U.S. Securities and Exchange Commission and Canadian regulatory authorities. See our most recent periodic report on or for a more extensive discussion of these and other risks. The Company does not assume any obligation to update its forward-looking statements.
 Gregory McKee Jennifer Matterson
 Vice President Corporate Communications Coordinator
 Development and CFO 350-4243 Glanford Avenue
 6055 Lusk Boulevard Victoria, BC CANADA V8Z 4B9
 San Diego, CA USA 92121 Tel: 250/744-2811
 Tel: 858/202-4900 Fax: 250/744-3331
 Dir: 858/202-4920
 Fax: 858/450-6849


 (Canadian dollars in thousands, except per share amounts)

 Year ended
 December 31,
 2004 2003 2002
 ---------- ---------- ----------
 Collaborative R&D revenue $ 700 $ 8,094 $ 8,370

 Operating expenses:
 Research and development 25,913 19,533 32,735
 Selling, general and administrative 6,385 6,170 7,326
 ---------- ---------- ----------
 32,298 25,703 40,061
 ---------- ---------- ----------

 Operating loss (31,598) (17,609) (31,691)
 ---------- ---------- ----------

 Other income (expenses):
 Interest income 787 700 1,266
 Net foreign exchange loss (938) (701) (332)
 Interest expense (96) (53) (69)
 ---------- ---------- ----------
 (247) (54) 865
 ---------- ---------- ----------
 Net loss from continuing operations (31,845) (17,663) (30,826)

 Net income from discontinued
 operations (a) 1,580 1,418 2,024
 ---------- ---------- ----------

 Net loss $ (30,265) $ (16,245) $ (28,802)
 ---------- ---------- ----------
 ---------- ---------- ----------

 Basic and diluted loss per
 common share: (b)
 From continuing operations $ (0.44) $ (0.29) $ (0.52)
 From discontinued operations 0.02 0.03 0.03
 ---------- ---------- ----------
 $ (0.42) $ (0.26) $ (0.49)
 ---------- ---------- ----------
 ---------- ---------- ----------

 Weighted average common shares
 outstanding (in thousands) 72,504 61,458 58,986

 (a) As of December 31, 2004 Stressgen plans to sell its bioreagent
 business in 2005 to focus corporate strategy and management resources
 and provide working capital to fund further development and
 commercialization of HspE7. The net income from discontinued
 operations is comprised of the following:

 Year ended
 December 31,
 2004 2003 2002
 ---------- ---------- ----------

 Revenue $ 5,772 $ 5,325 $ 5,672
 Operating expenses (4,074) (3,777) (3,658)
 Other (expenses) income (118) (130) 10
 ---------- ---------- ----------
 Net income from discontinued
 operations $ 1,580 $ 1,418 $ 2,024
 ---------- ---------- ----------
 ---------- ---------- ----------

 (b) Certain per share amounts will not recalculate exactly due to

 (Canadian dollars in thousands)

 December 31, December 31,
 2004 2003
 ------------ ------------

 Cash and short-term investments, continuing
 operations $ 21,578 $ 51,843
 Cash and short-term investments,
 discontinued operations 1,066 247
 Total assets, continuing operations 27,727 54,848
 Total assets, discontinued operations 2,447 1,582
 Long-term obligations, continuing operations 1,427 2,672
 Stockholders' equity, continuing operations 19,551 48,577

 Total shares outstanding (in thousands) 72,506 72,491

CONTACT: Gregory McKee, Vice President Corporate Development and CFO, 6055 Lusk Boulevard, San Diego, CA, USA, 92121, Tel: (858) 202-4900, Dir: (858) 202-4920, Fax: (858) 450-6849,; Jennifer Matterson, Communications Coordinator, 350-4243 Glanford Avenue, Victoria, BC, CANADA, V8Z 4B9, Tel: (250) 744-2811, Fax: (250) 744-3331,
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1CANA
Date:Mar 14, 2005
Previous Article:Judge Blocks 2nd 'Emergency' Order on Safe Staffing, Hospitals Must Be in Compliance With RN Ratio Law Today.
Next Article:Monroe(R) 'Safe All-Around' Campaign Rewards Consumers for Getting New Shocks and Struts; Spring Promotion Offers Service Certificates and...

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters